Lead Product(s) : CTx-PDE6b
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Seroba Life Sciences
Deal Size : $39.0 million
Deal Type : Series B Financing
Details : Coave Therapeutics will use the proceeds to support: its lead clinical program CTx-PDE6b; Developing its AAV Ligand Conjugate platform; Developing its AAV Ligand Conjugate (‘ALIGATER’) platform; Partnerships in key disease areas to progress novel coA...
Product Name : CTx-PDE6b
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 21, 2021
Lead Product(s) : CTx-PDE6b
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Seroba Life Sciences
Deal Size : $39.0 million
Deal Type : Series B Financing